Analysis of PTEN mutation in non-familial pheochromocytoma

Annals of the New York Academy of Sciences

Volumn 1073, Issue , 2006, Pages 317-331

  Puc, Janusz ^a,b,c   Placha, Grzegorz ^b   Wocial, Bozenna ^b   Podsypanina, Katrina ^a   Parsons, Ramon ^a   Gaciong, Zbigniew ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

IGF II; Pheochromocytoma; PTEN

Indexed keywords

ADRENALIN; CATECHOLAMINE DERIVATIVE; DNA; NORADRENALIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN B;

ADRENAL GLAND; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; EXON; FEMALE; GENE SEQUENCE; GROWTH; HORMONE ACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PHEOCHROMOCYTOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA SPLICING; UPREGULATION;

ANIMALIA;

EID: 33845488765     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1353.037     Document Type: Conference Paper

References (37)

1. MANGER, W.M. & R.W. GIFFORD. 1996. Clinical and Experimental Pheochromocytoma. Blackwell Science. Cambridge, MA.
2. WALLACE, M.R. et al. 1990. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 249: 181-186.
3. PACAK, K. et al. 2001. Pheochromocytoma. In Adrenal Disorders. A.N. Margioris & G.P. Chrousos, Eds.: 379-413. Humana Press. Totowa, NJ.
4. CARLSON, K.M. et al. 1994. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl Acad. Sci. US A 91: 1579-1583.
5. ENG, C. et al. 1994. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum. Mol. Genet. 3: 237-241.
6. ENG, C. et al. 1995. Mutations in the RET proto-oncogene and the von HippelLindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J. Med. Genet. 32: 934-937.
7. GIMENEZ-ROQUEPLO, A.P. et al. 2002. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J. Clin. Endocrinol. Metab. 87: 4771-4774.
8. GIMM, O. et al. 2000. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res. 60: 6822-6825.
9. NEUMANN, H.P. et al. 2002. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346: 1459-1466.
10. LI, J. et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275: 1943-1947.
11. STECK, P.A. et al. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15: 356-362.
12. LI, D.M. & H. SUN. 1997. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57: 2124-2129.
13. FEILOTTER, H.E. et al. 1999. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br. J. Cancer. 79: 718-723.
14. RHEI, E. et al. 1997. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 57: 3657-3659.
15. CAIRNS, P. et al. 1997. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57: 4997-5000.
16. WANG, S.I., R. PARSONS & M. ITTMANN. 1998. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin. Cancer Res. 4: 811-815.
17. TASHIRO, H. et al. 1997. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57: 3935-3940.
18. RISINGER, J.I. et al. 1997. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57: 4736-4738.
19. WANG, S.I. et al. 1997. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57: 4183-4186.
20. CHIARIELLO, E. et al. 1998. PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene. 16: 541-545.
21. GULDBERG, P. et al. 1997. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57: 3660-3663.
22. REIFENBERGER, J. et al. 2000. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch. 436: 487-493.
23. LIAW, D. et al. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 16: 64-67.
24. MARSH, D.J. et al. 1997. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet. 16: 333-334.
25. DI CRISTOFANO, A. et al. 1998. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19: 348-355.
26. PODSYPANINA, K. et al. 1999. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl Acad. Sci. USA 96: 1563-1568.
27. PODSYPANINA, K. et al. 2001. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten± mice. Proc. Natl Acad. Sci. USA 98: 10320-10325.
28. SATO, K. et al. 2002. Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer. Virchows Arch. 440: 160-165.
29. DAMMANN, R. et al. 2005. Frequent promoter methylation of tumor-related genes in sporadic and men2-associated pheochromocytomas. Exp. Clin. Endocrinol. Diabetes. 113: 1-7.
30. GELATO, M.C. & J. VASSALOTTI. 1990. Insulin-like growth factor-II: possible local growth factor in pheochromocytoma. J. Clin. Endocrinol. Metab. 71: 1168-1174.
31. SUZUKI, T. et al. 1992. Immunocytochemical demonstration of IGF-II immunore activity in human phaeochromocytoma and extra-adrenal abdominal paragan-glioma. J. Pathol. 167: 199-203.
32. SUZUKI, A. et al. 1998. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8: 1169-1178.
33. VISKOCHIL, D. et al. 1990. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 62: 187-192.
34. BRAUCH, H. et al. 1997. Sporadic pheochromocytomas are rarely associated with germline mutations in the VHL tumor suppressor gene or the ret protooncogene. J. Clin. Endocrinol. Metab. 82: 4101-4104.
35. BAR, M. et al. 1997. Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. Clin. Endocrinol. (Oxf). 47: 707-712.
36. HWANG, P.H. et al. 2005. PTEN/MMAC1 enhances the growth inhibition by anticancer drugs with downregulation of IGF-II expression in gastric cancer cells. Exp. Mol. Med. 37: 391-398.
37. KANG-PARK, S. & Y.I. LEE. 2003. PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN down-regulates IGF-II expression in hepatoma cells. FEBS Lett. 545: 203-208.